TCL Archive In Brief: NCI Awards $1.2 Million To Mt. Sinai To Establish Specialized Cancer Center July 26, 1974
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs January 17, 1992
